BlackRock Inc. boosted its position in AtriCure Inc. (NASDAQ:ATRC) by 22.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,731,558 shares of the medical device company’s stock after acquiring an additional 494,306 shares during the quarter. BlackRock Inc. owned 0.08% of AtriCure worth $49,823,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in AtriCure in the fourth quarter valued at approximately $203,000. Capital Fund Management S.A. raised its holdings in AtriCure by 57.3% in the fourth quarter. Capital Fund Management S.A. now owns 15,100 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 5,500 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in AtriCure in the third quarter valued at approximately $457,000. JPMorgan Chase & Co. acquired a new stake in AtriCure in the third quarter valued at approximately $771,000. Finally, Bank of Montreal Can raised its holdings in AtriCure by 398.7% in the fourth quarter. Bank of Montreal Can now owns 43,737 shares of the medical device company’s stock valued at $798,000 after acquiring an additional 34,967 shares in the last quarter. 87.50% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts recently weighed in on ATRC shares. Canaccord Genuity raised their target price on shares of AtriCure from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of AtriCure in a report on Tuesday, February 27th. Piper Jaffray reaffirmed a “buy” rating and issued a $24.00 target price on shares of AtriCure in a report on Sunday, December 10th. BidaskClub raised shares of AtriCure from a “hold” rating to a “buy” rating in a report on Saturday, March 17th. Finally, TheStreet upgraded shares of AtriCure from a “d+” rating to a “c-” rating in a research note on Friday, March 16th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. AtriCure presently has an average rating of “Buy” and a consensus price target of $24.80.
In other AtriCure news, SVP Justin J. Noznesky sold 4,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $17.03, for a total value of $68,120.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. The disclosure for this sale can be found here. Corporate insiders own 10.00% of the company’s stock.
Shares of AtriCure stock opened at $19.93 on Friday. The company has a market capitalization of $701.57, a price-to-earnings ratio of -24.01 and a beta of 0.26. AtriCure Inc. has a 52 week low of $14.88 and a 52 week high of $25.18. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.87 and a current ratio of 2.58.
AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Monday, February 26th. The medical device company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.13. The company had revenue of $46.06 million for the quarter, compared to analyst estimates of $45.85 million. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. The firm’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.27) earnings per share. analysts anticipate that AtriCure Inc. will post -0.83 EPS for the current fiscal year.
WARNING: “BlackRock Inc. Has $49.82 Million Position in AtriCure Inc. (ATRC)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/blackrock-inc-has-49-82-million-position-in-atricure-inc-atrc.html.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.